Prospective randomised pilot trial (n=30) comparing outpatient IV ketamine (0.5 mg/kg/hr) vs ketamine+magnesium vs magnesium control in military patients with chronic neuropathic pain; PTSD outcomes are secondary.
Randomised, factorial, double-blind outpatient trial enrolling military-affiliated adults with chronic neuropathic pain to evaluate IV ketamine infusions (0.5 mg/kg/hr) alone or combined with magnesium, versus a magnesium control with delayed reassignment.
Infusions are administered in a diminishing schedule over 24 weeks (Weeks 1–2: 3/week; Weeks 3–4: 2/week; Weeks 5–6: 1/week; boosters at weeks 10 and 24). Outcomes include self-reported pain, PTSD questionnaires, anxiety, depression, quality of life, and medication use.
IV ketamine infusions 0.5 mg/kg/hr over 4 h in a diminishing schedule across 24 weeks.
Infused in 250 mL NS at 62.5 mL/hr over 4 h; dose calculated per IBW formula.
IV ketamine (0.5 mg/kg/hr) combined with magnesium sulfate (3 g per infusion) over 4 h.
Ketamine infused in 250 mL NS at 62.5 mL/hr over 4 h; dose per IBW.
Magnesium sulfate 3 g (750 mg/hr) diluted into 250 mL NS and infused over 4 h (reported as active comparator; encoded as placebo reference with notes).
Magnesium sulfate 3 g infusion over 4 h; delayed control group reassigned after 2 weeks to an active treatment.
Magnesium sulfate 3 g (750 mg/hr) in 250 mL NS over 4 h; delayed-control reassigned after 2 weeks.